London · Delayed Price · Currency is GBP · Price in GBX GSK plc Earnings Call Transcripts
Fiscal Year 2026
-
The acquisition brings two late-stage, best-in-class oncology assets targeting ALK and ROS1 mutations, accelerating entry into lung cancer and supporting long-term revenue growth. Financial discipline, rapid integration, and strong physician feedback underpin confidence in clinical and commercial success.
-
The discussion highlighted a strategic pivot to precision oncology, leveraging both internal innovation and external acquisitions. Key assets like B7-H4, B7-H3, dostarlimab, and velzatinib are advancing, with significant data readouts expected in the next year to support long-term growth.
-
Bepirovirsen achieved functional cure in up to 26% of virologically suppressed chronic hepatitis B patients in phase III trials, with an additional 30% reaching partial cure. The therapy demonstrated an acceptable safety profile and is positioned as a first-in-class finite treatment, with regulatory approvals anticipated soon.
-
Q1 2026 saw 5% sales growth to £7.6B, led by Specialty Medicines and Shingrix, with core operating profit up 10% and EPS up 9%. HIV and oncology portfolios delivered strong growth, while pipeline and capital allocation remain focused on high-value assets and late-stage development.
-
Major clinical milestones are expected this year for camlipixant in chronic cough and bepirovirsen in hepatitis B, both targeting significant unmet needs. The R&D strategy emphasizes validated mechanisms, differentiation, and AI-driven innovation, with a broad pipeline in respiratory and specialty medicine.
-
No major strategic changes are planned under new leadership, with continued focus on core therapy areas and pipeline acceleration. Recent M&A targets scientifically de-risked assets, while new product launches in respiratory, oncology, and HIV are progressing well. Long-acting HIV therapies and broader respiratory segmentation are key growth drivers.
-
Significant pipeline momentum was highlighted, with multiple late-stage assets, key approvals in respiratory and oncology, and advances in hepatitis B and HIV. AI and partnerships are driving R&D productivity, while business development focuses on long-acting agents and near-term growth.
Fiscal Year 2025
-
Sales rose 7% to over £32 billion in 2025, led by Specialty Medicines and strong HIV and vaccine growth. Core profit and EPS grew double digits, with robust cash flow and increased dividends. 2026 guidance targets continued growth, with focus on new launches and pipeline acceleration.
-
The discussion outlined a focused R&D strategy integrating internal innovation and external acquisitions, with capital allocation driven by medical need and commercial potential. Key areas include oncology, respiratory, HIV, and fibrosis, with upcoming catalysts in hepatitis B, cough, and ADCs. Financial discipline and technology integration underpin portfolio decisions.
-
Q3 2025 saw 8% sales growth, 11% core operating profit growth, and 14% EPS growth, driven by Specialty Medicines, Oncology, and HIV. Upgraded guidance for 2025 reflects strong momentum, robust R&D progress, and continued investment in innovation and shareholder returns.
-
Upgraded guidance reflects strong specialty and HIV growth, with oncology and respiratory assets driving momentum. Multiple launches and positive phase III data underpin confidence, while regulatory and pricing challenges are being actively managed. Key products like Blenrep, depemokimab, and Shingrix are expected to outperform consensus.
-
Q2 2025 saw 6% sales growth, 12% core operating profit growth, and 15% EPS growth, led by specialty medicines and vaccines. Guidance was raised to the top end for 2025, with strong R&D progress, robust cash generation, and continued investment in pipeline and shareholder returns.
-
Q1 2025 saw 4% sales growth and 5% EPS increase, led by Specialty Medicines and strong HIV momentum, offsetting vaccine declines. Guidance for 2025 is reaffirmed, with robust cash flow, increased shareholder returns, and continued R&D investment supporting long-term growth.
-
Key 2025 drivers include Blenrep's relaunch, Nucala's COPD entry, and Shingrix's evolving strategy. Blenrep aims for broad use with strong survival data, while vaccine and specialty portfolios target growth through new indications and global expansion.
-
Strong sales and profit growth in 2024 are driven by specialty medicines and vaccines, with five major product launches expected in 2025, including Blenrep and Depimocumab. R&D and business development remain top priorities, supporting a robust pipeline and sustained margin improvement.
Fiscal Year 2024
-
2024 saw 8% sales growth to GBP 31 billion, led by specialty medicines and strong HIV performance, offsetting vaccine headwinds. Outlook for 2025 is 3–5% sales growth, with five major approvals expected and a GBP 2 billion share buyback planned.
-
Significant R&D momentum is driving a robust pipeline in oncology, respiratory, and liver disease, with multiple late-stage assets, innovative biomarker strategies, and increased investment in high-growth areas. Regulatory catalysts and data readouts are expected to sustain growth through the decade.
-
Strong sales and profit growth continue, driven by specialty medicines and a robust pipeline with multiple late-stage assets. Vaccines face near-term headwinds but maintain long-term growth ambitions, while disciplined capital allocation supports innovation and shareholder returns.
-
Clear R&D focus on vaccines, infectious diseases, respiratory, and oncology is driving portfolio growth. Arexvy and Shingrix show strong efficacy, with new data and label expansions expected. Key late-stage assets like gepotidacin, Bepirovirsen, Depemokimab, and Blenrep are advancing toward major milestones.
-
Significant progress has been made in pipeline prioritization, specialty and vaccine growth, and balance sheet transformation. Upgraded long-term outlooks, strong business development, and a focus on innovation and AI position the company for continued growth, with robust performance in HIV, oncology, and international markets.
-
Year-to-date sales grew 9% and profit 19%, led by specialty medicines and strong pipeline progress. Despite near-term vaccine headwinds and U.S. policy impacts, guidance for 2024 and long-term growth outlooks remain robust, with five major launches expected in 2025.
-
Management highlighted strong execution, upgraded financial guidance, and a robust specialty care and vaccine pipeline. Arexvy and Shingrix are key growth drivers, with international expansion and innovation in HIV and oncology. Zantac litigation remains a monitored risk.
-
Q2 saw 13% sales growth and 21% core operating profit increase, driven by strong specialty medicines, HIV, and general medicines. Upgraded 2024 guidance reflects confidence in continued growth, despite US vaccine headwinds and ongoing Zantac litigation.
-
Significant clinical advances in oncology are highlighted, with Blenrep showing strong efficacy and manageable safety in multiple myeloma, and regulatory filings planned for major markets. The pipeline includes promising assets in myelofibrosis, ovarian, endometrial, and solid tumors, with a focus on differentiated ADCs and immuno-oncology combinations.